NCT00231166View on ClinicalTrials.gov

Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Multiple Myeloma
Interventions
DRUG

HCD122

Trial Locations (7)

3181

Novartis Investigative Site, Prahran

4029

Novartis Investigative Site, Herston

10011

St. Vincent's Comprehensive Cancer Center Dept. of St. Vincent's Cancer, New York

19104

University of Pennsylvania--Abramson Cancer Center StudyCoordinator:CHCD122A2102, Philadelphia

97239

Oregon Health Sciences University, Portland

98109

Fred Hutchinson Cancer Research Center Dept. of FHCRC, Seattle

02115

Dana Farber Cancer Institute StudyCoordinator:CHCD122A2102, Boston

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY